Revista da Sociedade Portuguesa de Dermatologia e Venereologia (Jan 2023)

Erythema multiforme caused by topical imiquimod 3.75%

  • César Magalhães,
  • André Coelho,
  • Miguel Costa,
  • Nuno Menezes

Journal volume & issue
Vol. 81, no. 1

Abstract

Read online

Imiquimod, 3.75% cream, is a topical immunomodulator approved for treating actinic keratoses. Although local side effects are more frequent, it can also have systemic side effects. We report that imiquimod 3.75% can also produce erythema multiforme (EM), thus discarding it as an alternative to imiquimod 5% on this adverse effect.